Immunogen (IMGN) Tops Q2 EPS by 11c

Immunogen (NASDAQ: IMGN) reported Q2 EPS of ($0.02), $0.11 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $77.4 million versus the consensus estimate of $49.15 million.

For earnings history and earnings-related data on Immunogen (IMGN) click here.

You May Also Be Interested In

• Berkshire shares climb to highest level under Abel on strong results, new stakes
• Jefferies adds Uber to 'Franchise Picks' as bullish setup strengthens
• monday.com Ltd. (MNDY) Tops Q2 EPS by 37c; offers guidance